Analysis for PFE

📈 Growth & Financial Trajectory

Pfizer demonstrates an 8-quarter progression from Q2 2024 to Q1 2026 where Revenue grows from about $13.28B to about $14.45B, supporting an overall gain of roughly 8–9% despite a mid-period dip in 2025. Net income expands from about $0.05B to $2.70B by Q1 2026, reflecting a shift toward a steadier earnings trajectory.

💰 Margins & Cash Flow

Gross margins run in the ~70–76% range, indicating robust profitability. Operating margins are more variable, including a brief Q2 2025 dip, but cash flow remains generally positive: Net Cash Flow From Operating Activities is solid in most quarters, with a notable negative quarter in 2025-Q2; investing cash flow is typically negative as capex supports growth.

🛡️ Balance Sheet & Liquidity

Assets are around $206–208B, with Liabilities near $117–126B and Equity around $88–93B. Current assets vs current liabilities yields a modest liquidity cushion (roughly 1.0–1.3x in observed quarters), indicating resilience through cycles.

⚠️ Key Drivers & Risks

• Drivers: Broad pharma portfolio supporting vaccines/oncology; potential uplift from pricing/pipeline milestones.
• Risks: Revenue volatility and regulatory/patent cycles; sensitivity to pricing pressures and competition.